Wave Life Sciences LTD 8-K filings

Takeda Pharmaceutical Company has terminated its option for the Huntingtin target, ending its collaboration with Wave Life Sciences, which now has full control of its Huntington's disease program.

Wave Life Sciences is progressing its RNA therapeutics pipeline, showcasing positive clinical data for multiple programs and securing strategic collaborations to expand its reach.

Wave Life Sciences has priced an upsized public offering expected to generate approximately $200 million in gross proceeds.

Wave Life Sciences reported positive interim data from its Phase 2 clinical trial of WVE-N531, showing promising dystrophin expression and safety results for boys with Duchenne muscular dystrophy.

Wave Life Sciences shareholders approved an increase in shares authorized for issuance under the 2021 Equity Incentive Plan and re-elected nine existing directors at the 2024 Annual General Meeting.

Wave Life Sciences announced its second quarter 2024 financial results and provided a business update, highlighting positive clinical data and progress across its RNA medicines pipeline.

Wave Life Sciences reports positive results from its Phase 1b/2a SELECT-HD trial, demonstrating significant allele-selective mutant huntingtin lowering in Huntington's disease patients.

Wave Life Sciences announced its first quarter 2024 financial results and provided updates on its RNA medicine programs, including progress in clinical trials and collaborations.

Wave Life Sciences announced its fourth quarter and full year 2023 financial results, highlighting advancements in its clinical programs and a solid cash runway into the fourth quarter of 2025.